Roche’s treatment for Huntington’s disease has received a priority designation by the European regulator, sparking hope that a cure may be in the pipeline.
The US drug regulator has approved Mulpleta (lusutrombopag) as a treatment for thrombocytopenia in certain patients with chronic liver disease who are about to undergo a medical procedure.<
